A: According to published clinical trial data for FDA-approved medications: Wegovy (semaglutide 2.4 mg): Average 15% body weight loss at 68 weeks (approximately 33 pounds for 220-pound individual) Zepbound (tirzepatide 15 mg): Average 20% body weight loss at 72 weeks (approximately 44 pounds for 220-pound individual) Critical Context : These represent average results from controlled clinical trials where participants also followed reduced-calorie diets and increased physical activity
The GIP receptor component works alongside GLP-1 to amplify the insulin response, and the glucagon receptor component, which is absent in semaglutide and tirzepatide, signals the body to burn stored fat rather than conserve it
Legal Consequences: Possession and use of these substances can have legal repercussions, including fines and criminal charges
A washout period should also be observed between taking the last dose of a GLP-1 agonist and trying to conceive this is one month for tirzepatide, two months for semaglutide and 12 weeks for exenatide
Heres how Kochevar lost the weight and got healthier: Gaining, Losing and Regaining Kochevar says many people in his family are heavy, and he was always a big kid who ate a lot and hardly got any physical activity